NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Price Target & More

$14.85 +0.10 (+0.68 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$14.85
Today's Range$14.65 - $14.95
52-Week Range$11.90 - $20.40
Volume519,914 shs
Average Volume628,296 shs
Market Capitalization$743.96 million
P/E Ratio-42.43
Dividend YieldN/A
Beta1.12

About Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio2.41%
Quick Ratio2.40%

Price-To-Earnings

Trailing P/E Ratio-42.43
Forward P/E Ratio-165.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$165.08 million
Price / Sales4.54
Cash FlowN/A
Price / CashN/A
Book Value$2.92 per share
Price / Book5.09

Profitability

EPS (Most Recent Fiscal Year)($0.35)
Net Income$-15,560,000.00
Net Margins-9.43%
Return on Equity-11.94%
Return on Assets-7.53%

Miscellaneous

Employees273
Outstanding Shares50,440,000

How to Become a New Pot Stock Millionaire

Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.08. The biopharmaceutical company earned $44.28 million during the quarter, compared to analyst estimates of $44 million. Vanda Pharmaceuticals had a negative net margin of 9.43% and a negative return on equity of 11.94%. The company's quarterly revenue was up 15.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.08 earnings per share. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Vanda Pharmaceuticals.

What price target have analysts set for VNDA?

5 brokerages have issued 12-month price targets for Vanda Pharmaceuticals' shares. Their predictions range from $18.00 to $27.00. On average, they expect Vanda Pharmaceuticals' share price to reach $22.40 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a drop in short interest in the month of March. As of March 29th, there was short interest totalling 2,380,973 shares, a drop of 29.3% from the March 15th total of 3,367,547 shares. Based on an average daily trading volume, of 1,242,810 shares, the days-to-cover ratio is presently 1.9 days. Approximately 4.9% of the company's stock are sold short.

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 58)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Principal Accounting Officer & Treasurer (Age 52)
  • Mr. Richard L. Gulino, Sr. VP, Gen. Counsel and Sec. (Age 55)
  • Mr. Gian Piero Reverberi, Chief Commercial Officer and Sr. VP
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel.

Has Vanda Pharmaceuticals been receiving favorable news coverage?

Media stories about VNDA stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of 0.13 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.88 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $14.85.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $743.96 million and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (VNDA)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  308 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Vanda Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.40, suggesting that the stock has a possible upside of 50.84%. The high price target for VNDA is $27.00 and the low price target for VNDA is $18.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.40$22.1667$21.8333$21.8333
Price Target Upside: 50.84% upside30.24% upside53.22% upside36.46% upside

Vanda Pharmaceuticals (NASDAQ:VNDA) Consensus Price Target History

Price Target History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018OppenheimerReiterated RatingBuyLowView Rating Details
2/28/2018Seaport Global SecuritiesReiterated RatingBuy$21.00LowView Rating Details
2/13/2018Jefferies GroupReiterated RatingBuy$20.00LowView Rating Details
10/19/2017Piper JaffraySet Price TargetBuy$26.00N/AView Rating Details
8/3/2017HC WainwrightSet Price TargetBuy$18.00HighView Rating Details
4/12/2017CIBCReiterated RatingOutperform -> Outperform$21.00LowView Rating Details
11/9/2016AegisInitiated CoverageBuy$24.00N/AView Rating Details
10/10/2016Brean CapitalSet Price TargetBuy$24.00N/AView Rating Details
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 -> $22.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Vanda Pharmaceuticals (NASDAQ:VNDA) Earnings History and Estimates Chart

Earnings by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.12)($0.03)($0.08)
Q2 20183($0.06)$0.02($0.01)
Q3 20183($0.57)$0.07($0.16)
Q4 20183($0.06)$0.12$0.06

Vanda Pharmaceuticals (NASDAQ VNDA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.17)N/AView Earnings Details
2/14/2018Q4 2017($0.12)($0.04)$44.00 million$44.28 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.10)($0.10)$43.90 million$41.30 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.21)($0.03)$40.31 million$42.06 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.13)($0.17)$38.35 million$37.42 millionViewListenView Earnings Details
2/15/2017Q416($0.06)($0.01)$39.38 million$38.24 millionViewListenView Earnings Details
11/2/2016Q316($0.14)($0.01)$38.05 million$38.48 millionViewListenView Earnings Details
7/27/2016Q216($0.23)($0.11)$36.03 million$36.02 millionViewListenView Earnings Details
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details
2/10/2011($0.02)$0.08ViewN/AView Earnings Details
11/3/2010Q3 2010$0.03$0.11ViewN/AView Earnings Details
8/5/2010Q2 2010$0.10$0.04ViewN/AView Earnings Details
5/4/2010Q1 2010$0.06$0.02ViewN/AView Earnings Details
2/16/2010Q4 2009($0.25)($0.34)ViewN/AView Earnings Details
11/2/2009Q3 2009($0.30)($0.28)ViewN/AView Earnings Details
8/10/2009Q2 2009($0.26)($0.46)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.22)($0.24)ViewN/AView Earnings Details
2/11/2009Q4 2008($0.42)($0.28)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.44)($0.41)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.70)($0.51)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.86)($0.72)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.76)($0.78)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vanda Pharmaceuticals (NASDAQ:VNDA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 81.04%
Insider Trading History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2018Gunther BirznieksSVPSell8,525$18.72$159,588.00148,366View SEC Filing  
3/1/2018James Patrick KellyCFOSell8,532$18.72$159,719.04208,066View SEC Filing  
3/1/2018Mihael Hristos PolymeropoulosInsiderSell60,966$18.72$1,141,283.521,243,838View SEC Filing  
1/2/2018Gunther BirznieksSVPSell8,568$15.26$130,747.68118,366View SEC Filing  
1/2/2018James Patrick KellyCFOSell9,155$15.35$140,529.25144,721View SEC Filing  
1/2/2018Mihael Hristos PolymeropoulosInsiderSell191,760$15.30$2,933,928.001,031,848View SEC Filing  
1/3/2017Richard L GulinoSVPSell10,900$15.51$169,059.0012,500View SEC Filing  
9/23/2016James E FlynnInsiderSell1,120,461$16.56$18,554,834.16View SEC Filing  
9/19/2016James E FlynnInsiderSell547,886$15.66$8,579,894.76View SEC Filing  
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.4460,772View SEC Filing  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88839,178View SEC Filing  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.8040,665View SEC Filing  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52816,781View SEC Filing  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.0015,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vanda Pharmaceuticals (NASDAQ VNDA) News Headlines

Source:
DateHeadline
Vanda Pharmaceuticals (VNDA) Rating Increased to Buy at Zacks Investment ResearchVanda Pharmaceuticals (VNDA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:54 AM
Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018
finance.yahoo.com - April 19 at 9:59 AM
Vanda Pharmaceuticals (VNDA) Downgraded by Zacks Investment ResearchVanda Pharmaceuticals (VNDA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 17 at 3:34 PM
Patent on Vanda schizophrenia drug upheld by appeals courtPatent on Vanda schizophrenia drug upheld by appeals court
www.reuters.com - April 15 at 4:22 PM
Vanda Pharmaceuticals (VNDA) Says It Won Case on FanaptVanda Pharmaceuticals (VNDA) Says It Won Case on Fanapt
www.streetinsider.com - April 15 at 4:22 PM
Vanda Pharmaceuticals Inc. (VNDA) Sees Significant Decline in Short InterestVanda Pharmaceuticals Inc. (VNDA) Sees Significant Decline in Short Interest
www.americanbankingnews.com - April 15 at 1:14 AM
Vanda Pharmaceuticals (VNDA) Given a $21.00 Price Target at OppenheimerVanda Pharmaceuticals (VNDA) Given a $21.00 Price Target at Oppenheimer
www.americanbankingnews.com - April 13 at 8:19 PM
Vanda Pharmaceuticals (VNDA) Given a $18.00 Price Target by HC Wainwright AnalystsVanda Pharmaceuticals (VNDA) Given a $18.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 13 at 7:15 PM
Vanda Pharmaceuticals (VNDA) PT Set at $23.00 by Piper JaffrayVanda Pharmaceuticals (VNDA) PT Set at $23.00 by Piper Jaffray
www.americanbankingnews.com - April 13 at 5:29 PM
Vanda Wins Appeal Case on Fanapt®Vanda Wins Appeal Case on Fanapt®
finance.yahoo.com - April 13 at 4:15 PM
Vanda Pharmaceuticals (VNDA) Lifted to Strong-Buy at Zacks Investment ResearchVanda Pharmaceuticals (VNDA) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - April 12 at 7:25 PM
Vanda Pharmaceuticals Target of Unusually High Options Trading (VNDA)Vanda Pharmaceuticals Target of Unusually High Options Trading (VNDA)
www.americanbankingnews.com - April 11 at 7:04 AM
$43.40 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter$43.40 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - April 10 at 2:23 AM
Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic DermatitisVanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis
finance.yahoo.com - April 9 at 4:16 PM
Jefferies Group Analysts Cut Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)Jefferies Group Analysts Cut Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - April 9 at 2:28 AM
-$0.09 Earnings Per Share Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter-$0.09 Earnings Per Share Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - April 8 at 7:10 PM
Vanda Pharmaceuticals (VNDA) Lowered to Sell at ValuEngineVanda Pharmaceuticals (VNDA) Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 4 at 6:23 PM
Oppenheimer Analysts Give Vanda Pharmaceuticals (VNDA) a $26.00 Price TargetOppenheimer Analysts Give Vanda Pharmaceuticals (VNDA) a $26.00 Price Target
www.americanbankingnews.com - April 4 at 3:32 PM
Vanda Pharmaceuticals (VNDA) Rating Lowered to Sell at ValuEngineVanda Pharmaceuticals (VNDA) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - March 31 at 11:34 PM
Oppenheimer Reiterates "Buy" Rating for Vanda Pharmaceuticals (VNDA)Oppenheimer Reiterates "Buy" Rating for Vanda Pharmaceuticals (VNDA)
www.americanbankingnews.com - March 30 at 1:48 PM
Vanda Pharmaceuticals Inc. (VNDA) Receives Average Rating of "Buy" from AnalystsVanda Pharmaceuticals Inc. (VNDA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 9:44 AM
Vanda receives notice of Teva application for generic HetliozVanda receives notice of Teva application for generic Hetlioz
seekingalpha.com - March 26 at 4:19 PM
Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Quarterly Sales of $43.40 MillionVanda Pharmaceuticals Inc. (VNDA) Expected to Post Quarterly Sales of $43.40 Million
www.americanbankingnews.com - March 24 at 2:38 AM
 Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) Will Post Earnings of -$0.09 Per Share Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - March 22 at 7:10 PM
Vanda Pharmaceuticals (VNDA) Receives "Buy" Rating from OppenheimerVanda Pharmaceuticals (VNDA) Receives "Buy" Rating from Oppenheimer
www.americanbankingnews.com - March 22 at 4:09 PM
Vanda Pharmaceuticals (VNDA) Stock Rating Lowered by BidaskClubVanda Pharmaceuticals (VNDA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 17 at 9:32 AM
Pre-Open Movers 03/16: (SEED) (DXR) (VERU) Higher; (OSTK) (TIF) (W) Lower (more...)Pre-Open Movers 03/16: (SEED) (DXR) (VERU) Higher; (OSTK) (TIF) (W) Lower (more...)
www.streetinsider.com - March 16 at 4:22 PM
Vanda Pharmaceuticals Inc. Prices Public Offering of Common StockVanda Pharmaceuticals Inc. Prices Public Offering of Common Stock
finance.yahoo.com - March 16 at 10:48 AM
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Investors Are Paying Above The Intrinsic ValueVanda Pharmaceuticals Inc (NASDAQ:VNDA) Investors Are Paying Above The Intrinsic Value
finance.yahoo.com - March 16 at 10:48 AM
Vanda Pharmaceuticals (VNDA) Proposes Public Offering of Common Stock - StreetInsider.comVanda Pharmaceuticals (VNDA) Proposes Public Offering of Common Stock - StreetInsider.com
www.streetinsider.com - March 14 at 4:15 PM
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock - PR Newswire (press release)Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock - PR Newswire (press release)
www.prnewswire.com - March 14 at 4:15 PM
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common StockVanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
finance.yahoo.com - March 14 at 4:15 PM
Equities Analysts Set Expectations for Vanda Pharmaceuticals Inc.s Q1 2018 Earnings (VNDA)Equities Analysts Set Expectations for Vanda Pharmaceuticals Inc.'s Q1 2018 Earnings (VNDA)
www.americanbankingnews.com - March 8 at 6:30 AM
Vanda Pharmaceuticals (VNDA) Reports Demonstrated Efficacy for HETLIOZ from Advanced Clinical Study - StreetInsider.comVanda Pharmaceuticals (VNDA) Reports Demonstrated Efficacy for HETLIOZ from Advanced Clinical Study - StreetInsider.com
www.streetinsider.com - March 7 at 4:16 PM
Vanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences - PR Newswire (press release)Vanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences - PR Newswire (press release)
www.prnewswire.com - March 7 at 4:16 PM
Vanda Pharmaceuticals Announces Participation at March 2018 Investor ConferencesVanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences
finance.yahoo.com - March 7 at 10:33 AM
A drug for jet lag? A D.C. drug developer says it just got a lot closer.A drug for jet lag? A D.C. drug developer says it just got a lot closer.
www.bizjournals.com - March 6 at 4:13 PM
Stonepine Capital Management LLC Has $13.45 Million Stake in Vanda Pharmaceuticals Inc. (VNDA)Stonepine Capital Management LLC Has $13.45 Million Stake in Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - March 6 at 2:53 PM
Vanda Pharmaceuticals Inc. (VNDA) Stake Boosted by University of Notre Dame DU LacVanda Pharmaceuticals Inc. (VNDA) Stake Boosted by University of Notre Dame DU Lac
www.americanbankingnews.com - March 6 at 10:02 AM
A drug for jet lag? A D.C. biotech says it just got a lot closer.A drug for jet lag? A D.C. biotech says it just got a lot closer.
finance.yahoo.com - March 5 at 4:25 PM
Vanda Pharmaceuticals (VNDA) Given a $27.00 Price Target at OppenheimerVanda Pharmaceuticals (VNDA) Given a $27.00 Price Target at Oppenheimer
www.americanbankingnews.com - March 5 at 1:35 PM
HETLIOZ® (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical StudyHETLIOZ® (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study
finance.yahoo.com - March 5 at 10:51 AM
Sei Investments Co. Grows Position in Vanda Pharmaceuticals Inc. (VNDA)Sei Investments Co. Grows Position in Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - March 5 at 7:36 AM
Vanda Pharmaceuticals Inc. (VNDA) Forecasted to Earn Q1 2018 Earnings of ($0.03) Per ShareVanda Pharmaceuticals Inc. (VNDA) Forecasted to Earn Q1 2018 Earnings of ($0.03) Per Share
www.americanbankingnews.com - March 5 at 1:10 AM
Vanda Pharmaceuticals Inc. (VNDA) Stake Lowered by Bogle Investment Management L P DEVanda Pharmaceuticals Inc. (VNDA) Stake Lowered by Bogle Investment Management L P DE
www.americanbankingnews.com - March 4 at 4:58 AM
Vanda Pharmaceuticals (VNDA) Lifted to "Strong-Buy" at BidaskClubVanda Pharmaceuticals (VNDA) Lifted to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 3 at 9:30 PM
Vanda Pharmaceuticals Inc. (VNDA) Given Consensus Rating of "Buy" by BrokeragesVanda Pharmaceuticals Inc. (VNDA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 3 at 4:15 PM
Insider Selling: Vanda Pharmaceuticals Inc. (VNDA) SVP Sells 8,525 Shares of StockInsider Selling: Vanda Pharmaceuticals Inc. (VNDA) SVP Sells 8,525 Shares of Stock
www.americanbankingnews.com - March 2 at 6:56 PM
Vanda Pharmaceuticals Inc. (VNDA) CFO James Patrick Kelly Sells 8,532 SharesVanda Pharmaceuticals Inc. (VNDA) CFO James Patrick Kelly Sells 8,532 Shares
www.americanbankingnews.com - March 2 at 6:56 PM
Insider Selling: Vanda Pharmaceuticals Inc. (VNDA) Insider Sells 60,966 Shares of StockInsider Selling: Vanda Pharmaceuticals Inc. (VNDA) Insider Sells 60,966 Shares of Stock
www.americanbankingnews.com - March 2 at 6:20 PM

SEC Filings

Vanda Pharmaceuticals (NASDAQ:VNDA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vanda Pharmaceuticals (NASDAQ:VNDA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vanda Pharmaceuticals (NASDAQ VNDA) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.